NICE (UK) positive for Libtayo (cemiplimab) for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy – Regeneron

NICE (UK): Cemiplimab can be used as an option to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults if: i) they have not had immunotherapy; ii) treatment is stopped after 32 cycles (each lasting 3 weeks), or earlier if the cancer progresses or there is unacceptable toxicity; and iii) the company provides cemiplimab according to the commercial arrangement.

Why the committee made these recommendations: Usual treatment for recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (with or without immunotherapy) is single-agent chemotherapy. Cemiplimab is licensed for people who have had platinum-based chemotherapy. This includes people who also had immunotherapy. But, for this evaluation, the company asked for cemiplimab to be considered only for people who have not had immunotherapy. Clinical trial evidence shows that cemiplimab increases how long people have before their cancer gets worse, and how long they live, compared with single-agent chemotherapy. In this trial, people could have cemiplimab for up to 32 cycles (each lasting 3 weeks). When considering the condition’s severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, cemiplimab can be used.